tiprankstipranks
Trending News
More News >
Sabra Healthcare REIT (SBRA)
NASDAQ:SBRA
Advertisement

Sabra Healthcare REIT (SBRA) AI Stock Analysis

Compare
1,081 Followers

Top Page

SBRA

Sabra Healthcare REIT

(NASDAQ:SBRA)

Rating:74Outperform
Price Target:
$21.00
▲(7.42% Upside)
Sabra Healthcare REIT's overall stock score reflects strong financial performance and positive earnings call sentiment, supported by strategic corporate events. The stock's valuation and technical indicators suggest moderate growth potential, with a high dividend yield providing additional appeal.
Positive Factors
Acquisitions
SBRA announced an additional $114.5M in SHOP acquisitions at yields between 7.5-7.7% with a pipeline of $220M under LOI, indicating future growth potential.
Financial Performance
2Q25 normalized AFFO of $0.38 beat market expectations, indicating strong financial performance.
Revenue Growth
Medicaid increases are expected for SBRA's skilled nursing facilities, which could improve revenue.
Negative Factors
Acquisition Volume
The acquisition volume is viewed as slightly light compared to bullish expectations, which could be seen as a limitation.
Earnings
1Q25 Normalized FFO was below expectations.
Financial Guidance
Management's guidance is for Core FFO to be within a range of $1.43-$1.46 per share ($1.445 midpoint), slightly below consensus of $1.48 per share.

Sabra Healthcare REIT (SBRA) vs. SPDR S&P 500 ETF (SPY)

Sabra Healthcare REIT Business Overview & Revenue Model

Company DescriptionAs of March 31, 2022, Sabra's investment portfolio included 416 real estate properties held for investment. This consists of (i) 279 Skilled Nursing/Transitional Care facilities, (ii) 59 Senior Housing communities (Senior Housing - Leased), (iii) 50 Senior Housing communities operated by third-party property managers pursuant to property management agreements (Senior Housing - Managed), (iv) 13 Behavioral Health facilities and (v) 15 Specialty Hospitals and Other facilities), one asset held for sale, one investment in a sales-type lease, 16 investments in loans receivable (consisting of (i) two mortgage loans, (ii) one construction loan and (iii) 13 other loans), seven preferred equity investments and one investment in an unconsolidated joint venture. As of March 31, 2022, Sabra's real estate properties held for investment included 41,445 beds/units, spread across the United States and Canada.
How the Company Makes MoneySabra Healthcare REIT generates revenue primarily through leasing its properties to healthcare operators under long-term, triple-net leases. In this arrangement, the tenants are responsible for property expenses such as maintenance, taxes, and insurance, allowing Sabra to receive steady rental income with reduced operational responsibilities. Key revenue streams include rental income from its diversified portfolio of skilled nursing facilities, senior housing, and other healthcare properties. Additionally, Sabra may benefit from rent escalators and the potential for property appreciation over time. The company also engages in strategic partnerships with operators in the healthcare sector, which can enhance occupancy rates and improve financial performance. Factors contributing to its earnings include demographic trends driving demand for healthcare services, effective property management, and a focus on high-quality, well-located assets.

Sabra Healthcare REIT Earnings Call Summary

Earnings Call Date:Aug 04, 2025
(Q2-2025)
|
% Change Since: 7.95%|
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Positive
The earnings call reflects strong investment activity and financial performance, buoyed by positive Medicaid and Medicare adjustments. However, challenges persist in transitioning the Holiday portfolio and finding skilled nursing opportunities.
Q2-2025 Updates
Positive Updates
Strong Investment Pipeline
Sabra Health Care REIT has closed on $122 million of senior housing investments and has been awarded about $220 million more, with a target of $500 million in investments for the year.
Improved Financial Performance
Normalized FFO and AFFO per share increased to $0.37 and $0.38, respectively, a 6% improvement over the same period in 2024.
Positive Medicaid and Medicare Adjustments
Medicaid rate increases averaging just above 5% for top skilled nursing tenants, and Medicare market basket finalized upward from 2.8% to 3.2%.
Strong Same-Store Portfolio Performance
Same-store managed senior housing portfolio revenue grew 5.6% year-over-year with a 17.1% increase in cash NOI.
Negative Updates
Holiday Transition Challenges
The transition of the Holiday portfolio led to some occupancy issues, impacting overall metrics.
Limited Skilled Nursing Opportunities
Challenges in finding quality skilled nursing deals, with a majority of opportunities still weighted towards SHOP.
Company Guidance
During the 2025 Sabra Second Quarter Earnings Call, the company provided guidance and insights into various financial metrics. Sabra expects its Medicaid rate increases to average around 3.5%, with top skilled nursing tenants seeing rates just above 5%. Medicare market basket rates are finalized upwards from 2.8% to 3.2%. The company has closed on or been awarded $350 million worth of deals, with a target of $500 million in investments for the year. Sabra's goal is to increase its SHOP (senior housing operating portfolio) to 30% by 2026, requiring $1 billion in investments. The same-store managed senior housing portfolio showed a revenue growth of 5.6% year-over-year, with occupancy increasing to 86%. Cash net operating income (NOI) rose 17.1% year-over-year. The company's updated 2025 earnings guidance includes normalized FFO per share of $1.45 to $1.47 and AFFO per share of $1.47 to $1.49. Sabra's leverage, as measured by the net debt to adjusted EBITDA ratio, decreased to 5x as of June 30, 2025. The company maintains a strong liquidity position of approximately $1.2 billion.

Sabra Healthcare REIT Financial Statement Overview

Summary
Sabra Healthcare REIT demonstrates strong revenue growth and improving profitability metrics. The balance sheet is stable with effective debt management, and cash flow is robust, supporting operational flexibility. However, historical profitability issues and high debt levels pose some risks.
Income Statement
78
Positive
Sabra Healthcare REIT has shown a strong revenue growth trajectory with a 13.29% increase from 2023 to 2024 and a 2.73% increase from 2024 to TTM. The gross profit margin remains solid, and the net profit margin has improved significantly from prior years. EBIT and EBITDA margins have also shown positive trends, indicating operational efficiency. However, the company faced challenges in profitability in earlier years, which slightly tempers the overall score.
Balance Sheet
72
Positive
The balance sheet of Sabra Healthcare REIT reflects a stable equity base with an equity ratio of 51.64% in TTM, indicating a strong capital structure. The debt-to-equity ratio has improved over recent periods, showcasing effective debt management. Return on equity has improved to 5.21% in TTM from earlier losses, enhancing shareholder value. Despite these strengths, the high level of total debt remains a potential risk factor.
Cash Flow
81
Very Positive
Cash flow statements reveal a robust free cash flow position, with consistent positive operating cash flow. The free cash flow to net income ratio is strong, reflecting efficient cash conversion. The operating cash flow to net income ratio is healthy, indicating strong cash-generating capabilities relative to reported earnings. There is positive free cash flow growth, suggesting solid cash flow management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue733.04M703.24M647.51M624.81M569.54M598.57M
Gross Profit503.68M476.15M269.18M462.20M428.34M467.02M
EBITDA475.39M412.61M311.81M323.35M166.21M417.96M
Net Income182.33M126.71M13.76M-77.61M-113.26M138.42M
Balance Sheet
Total Assets5.33B5.30B5.39B5.75B5.97B5.99B
Cash, Cash Equivalents and Short-Term Investments95.17M60.47M41.28M49.31M112.00M59.08M
Total Debt1.76B2.44B2.45B2.70B2.39B2.37B
Total Liabilities2.62B2.56B2.58B2.69B2.59B2.58B
Stockholders Equity2.71B2.74B2.80B3.06B3.38B3.41B
Cash Flow
Free Cash Flow338.84M310.54M300.57M315.73M322.78M249.26M
Operating Cash Flow338.84M310.54M300.57M315.73M356.39M354.85M
Investing Cash Flow-100.05M-109.00M103.13M-216.25M-336.20M-136.45M
Financing Cash Flow-179.44M-181.56M-410.30M-161.71M30.14M-202.11M

Sabra Healthcare REIT Technical Analysis

Technical Analysis Sentiment
Positive
Last Price19.55
Price Trends
50DMA
18.18
Positive
100DMA
17.66
Positive
200DMA
17.10
Positive
Market Momentum
MACD
0.36
Negative
RSI
73.52
Negative
STOCH
88.54
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBRA, the sentiment is Positive. The current price of 19.55 is above the 20-day moving average (MA) of 18.38, above the 50-day MA of 18.18, and above the 200-day MA of 17.10, indicating a bullish trend. The MACD of 0.36 indicates Negative momentum. The RSI at 73.52 is Negative, neither overbought nor oversold. The STOCH value of 88.54 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SBRA.

Sabra Healthcare REIT Risk Analysis

Sabra Healthcare REIT disclosed 44 risk factors in its most recent earnings report. Sabra Healthcare REIT reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sabra Healthcare REIT Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$7.61B28.818.36%3.63%50.84%104.44%
79
Outperform
$3.67B24.6810.49%4.62%6.87%7.23%
76
Outperform
$12.50B26.4310.47%6.34%12.73%23.51%
74
Outperform
$4.70B25.816.66%6.14%6.89%240.70%
73
Outperform
$1.68B20.038.94%6.20%8.18%-16.83%
70
Neutral
$7.25B-1.51%2.35%11.62%
53
Neutral
$1.23B2.93-5.63%5.65%-3.91%-97.46%
* Real Estate Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SBRA
Sabra Healthcare REIT
19.55
4.11
26.62%
LTC
LTC Properties
36.80
2.81
8.27%
NHI
National Health Investors
77.87
2.24
2.96%
OHI
Omega Healthcare
42.26
6.02
16.61%
CTRE
CareTrust REIT
34.44
6.45
23.04%
AHR
American Healthcare REIT, Inc.
42.47
22.03
107.78%

Sabra Healthcare REIT Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Sabra Healthcare REIT Announces New Equity Distribution
Neutral
Aug 5, 2025

On August 5, 2025, Sabra Health Care REIT, Inc. entered into a new equity distribution agreement with several financial institutions to issue and sell common stock shares, aiming to raise up to $750 million. This move replaces a prior agreement from February 2023, which was terminated on the same date, and is intended to support the company’s financial strategies, including debt repayment and potential future investments.

The most recent analyst rating on (SBRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Sabra Healthcare REIT stock, see the SBRA Stock Forecast page.

Private Placements and FinancingM&A TransactionsDividendsBusiness Operations and StrategyFinancial Disclosures
Sabra Healthcare REIT Updates 2025 Earnings Guidance
Positive
Aug 4, 2025

In the second quarter of 2025, Sabra Health Care REIT reported a net income of $0.27 per diluted share and announced several strategic investments, including a $53 million acquisition of a senior housing property. The company also transitioned 21 senior housing properties to new operators, aiming to enhance asset value. Sabra closed a $500 million unsecured term loan to refinance existing debt, reducing interest costs. The company updated its 2025 earnings guidance, reflecting positive trends in Medicare and Medicaid reimbursement rates, which are expected to support its skilled nursing portfolio. Sabra’s liquidity stood at $1.2 billion as of June 30, 2025, and the company declared a quarterly dividend of $0.30 per share.

The most recent analyst rating on (SBRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Sabra Healthcare REIT stock, see the SBRA Stock Forecast page.

Private Placements and FinancingBusiness Operations and Strategy
Sabra Healthcare REIT Redeems Senior Notes and Optimizes Capital
Positive
Jul 31, 2025

On July 30, 2025, Sabra Health Care REIT, Inc. and its subsidiaries entered into a $500 million unsecured credit agreement with several financial institutions, with the potential to increase borrowings to $1 billion. The agreement includes interest rate swaps that fix the SOFR portion of the interest rate, resulting in an effective rate of 4.64% through 2030. Additionally, Sabra redeemed its 5.125% Senior Notes due 2026 on July 31, 2025, at a cash redemption price of 100.575% of the principal, plus accrued interest. These financial maneuvers are expected to optimize Sabra’s capital structure and potentially enhance its financial flexibility.

The most recent analyst rating on (SBRA) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Sabra Healthcare REIT stock, see the SBRA Stock Forecast page.

Private Placements and FinancingBusiness Operations and Strategy
Sabra Healthcare REIT Announces Senior Notes Redemption
Neutral
Jun 30, 2025

On June 30, 2025, Sabra Health Care REIT, Inc. announced that its subsidiary, Sabra Health Care Limited Partnership, will redeem all $500 million of its outstanding 5.125% Senior Notes due 2026 on July 31, 2025. This redemption will be funded by issuing a $500 million term loan, and it will cease the accrual of interest on the Notes, impacting the company’s financial operations and potentially its market positioning.

The most recent analyst rating on (SBRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Sabra Healthcare REIT stock, see the SBRA Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Sabra Healthcare REIT Holds Annual Stockholders Meeting
Positive
Jun 12, 2025

On June 12, 2025, Sabra Healthcare REIT held its annual stockholders meeting where several key decisions were made. The stockholders elected seven directors to the board, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2025, and approved the executive compensation plan, reflecting continued confidence in the company’s leadership and strategic direction.

The most recent analyst rating on (SBRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Sabra Healthcare REIT stock, see the SBRA Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 14, 2025